With aims to become a 'generational biotech,' Zealand Pharma hires Lilly...
Fresh off a splashy obesity deal, Zealand Pharma is doubling down on its R&D ambitions with a new chief scientific officer. The Copenhagen-based biotech, which is partnered with Roche and...
View ArticleChina’s biotech market is staging a comeback that US biotech can only wish for
China’s biopharmaceutical sector is showing signs of revival from its post-pandemic slump, even as its US counterpart remains in a rut. Buoyed by licensing deals, improving company fundamentals and...
View ArticleVeraxa makes a SPAC deal; Illumina discloses layoffs
Plus, news about Innate Pharma, Sanofi, Claris Ventures and Rezolute: A rare SPAC deal: At a time when public markets are challenging for IPOs, a Swiss biotech plans to merge with ...
View ArticleTop pharma companies increased lobbying spend at start of 2025
Pfizer, Novartis, Amgen, Eli Lilly and Johnson & Johnson were the top congressional lobbying spenders among the major biopharma companies, as the industry faces a tumultuous environment in which...
View ArticleVaccine makers stand by their investments despite US headwinds
WASHINGTON — Representatives from large vaccine makers say they are committed to their pipelines, despite a new wave of scrutiny in the US that risks diminishing a major market. On a panel at the World...
View ArticleEurope 'falling behind' on drug R&D and manufacturing investments:...
AstraZeneca CEO Pascal Soriot called on Europe to step up investments and “protect its health sovereignty" as it falls behind the US on spending. His comments echo calls from other pharma CEOs who are...
View ArticleRoche Q1 earnings: CEO warns that tariffs could impact dealmaking
Roche said that its future dealmaking could be impacted by potential tariffs on pharmaceuticals. “If there are questions around tariffs, it will be more difficult to make financial sense of any M&A...
View ArticleSanofi Q1 earnings: Altuviiio closing in on blockbuster status, Dupixent...
Sanofi posted a strong set of first-quarter results Thursday morning, with its recombinant factor drug Altuviiio on track to become a blockbuster drug and its crown jewel Dupixent continuing to draw...
View ArticleMerck Q1 earnings: Gardasil sales hit by China market pressure
Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China. Gardasil is Merck’s second-biggest product behind its megablockbuster...
View ArticleRoche takes steps to protect itself from tariffs, while Sanofi hangs back
Roche and Sanofi said on Thursday morning they have been running scenarios on how US and other tariffs could potentially impact their respective businesses. However, while Roche has detailed specific...
View ArticleThermo Fisher buckles up for US-China trade war, budgets $2B to ease impact
Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff war and NIH funding cuts. Because of the "substantial" US tariff rates on ...
View ArticleBristol Myers Q1 earnings: Transition continues as drugmaker raises guidance
Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported first-quarter earnings Thursday morning. While overall revenue declined by 6% to $11.2...
View ArticleVersant's latest biotech focuses on inflammatory diseases
Versant Ventures' biotech incubation team has launched another Swiss startup, this time focused on a pair of antibodies for autoimmune and inflammatory diseases. Granite Bio broke cover on Thursday...
View ArticleAvidicure's $50M seed round; Flagship's new AI company that detects disease
Plus, news about Novo Holdings, Bioxodes and Tempus AI: Dutch biotech raises $50M in seed funding: Avidicure, which is developing avidity engineered antibodies for cancer, said it plans to use the...
View ArticleLotte Bio launches ADC services; Ypsomed to focus on self-injection business
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lotte Biologics has launched its ADC services and it has signed its ...
View ArticleBristol Myers CEO signals dealmaking will be a top priority in 2025
Is Bristol Myers Squibb ready to take on big dealmaking again? When CEO Chris Boerner took over in late 2023, Bristol Myers was in a difficult position. Its stock price {$BMY} was down more than ...
View ArticleThe potential of all-AI labs
Picture this: A chemist, biologist and computer scientist are working together in a lab. But in this case, they’re all AI agents trained on reams of papers and data, working in a virtual lab run ...
View ArticleHalozyme launches patent fight over Merck's injectable Keytruda
San Diego biotech Halozyme is suing Merck over an injectable version of its blockbuster cancer drug, alleging that the new formulation will infringe on Halozyme's under-the-skin delivery patents. The...
View ArticleCassidy urges major reforms to 340B drug discount program
The growing drug discount program for low-income Americans, known as the 340B program, has "transparency and oversight concerns" and needs to be reformed, Sen. Bill Cassidy (R-LA), chair of the Senate...
View ArticleDrugmakers prepare for manageable tariff hit to business, earnings
For the drug industry, President Donald Trump's tariffs haven't started to really hurt. At least not yet. On Thursday, several of the world’s largest pharma companies — Merck, Bristol Myers Squibb,...
View ArticleBiosimilar launch challenges remain, report finds
As President Donald Trump has sought to speed the development and approval of new biosimilar competition to expensive biologics, only 66% of FDA-approved biosimilars have actually been commercialized,...
View ArticleMerck is well-stocked on Keytruda as pharma tariffs loom, CEO says
Merck CEO Rob Davis told investors on Thursday that he’s confident in the company’s ability to protect its top-selling product from the potential impacts of industry-specific tariffs. Without going...
View ArticleCaribou lays off 32% of staff, cuts lupus program
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid a bleak biotech market. Caribou said Thursday...
View ArticleGilead's strong HIV business balances out low Covid and cancer drug sales
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year. The Foster City ...
View Article